KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank83
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-3.73
↑ 39% vs avg
Percentile
P83
Within normal range
Streak
2 yr
Consecutive declineElevated
Average
-6.14
Historical baseline
PeriodValueYoY Change
2025-3.73-13.1%
2024-3.30-23.8%
2023-2.66+29.6%
2022-3.78+63.3%
2021-10.31-55.0%
2020-6.65+60.1%
2019-16.66-165.2%
2018-6.28-66.0%
2017-3.79+11.4%
2016-4.27-